



www.genfit.com

## GENFIT: MINUTES OF THE EXTRAORDINARY SHAREHOLDERS' MEETING OF DECEMBER 18<sup>TH</sup>, 2012

- **The resolutions proposed by the Management Board for the implementation of an €8M convertible bond loan agreement were approved by a large majority of shareholders.**

**Lille (France), Boston (Massachusetts, United States), December 18<sup>th</sup>, 2012** – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announced that its shareholders have approved all the resolutions proposed by the Management Board for the implementation of an €8M bond loan agreement, convertible into Company shares, at the Extraordinary Shareholders' Meeting held on December 18th, 2012 in Lille (France).

The two resolutions proposed by the Management Board for the shareholders' approval were adopted with 90.43% and 92.34% of the cast votes.

**Jean-François MOUNEY, Chairman and Chief Executive Officer of GENFIT, declared:** « *Following the first Extraordinary Shareholders' Meeting on October 31<sup>st</sup>, 2012, and thanks to the renewed approval of our shareholders, the Management Board now possesses a variety of delegations whose objective is to ensure the long-term financing of our most advanced research programs until their licensing to major players of the biopharmaceutical industry. In keeping with its tradition, the Company has developed a flexible framework that respects all its shareholders. Thus, the different measures designed to reinforce our cash balance and shareholders equity will be implemented according to our needs with the support of key shareholders accompanied by individual investors* ».

The two resolutions aimed to grant the Management Board:

- A delegation of authority to enable one or more reserved capital increases by the issue of bonds, convertible into new ordinary shares of the Company, and/or notes giving the right to subscribe to such bonds for a maximum nominal bond loan of 8 million Euros (€8,000,000); the authorization of the corresponding capital increase(s) and the suppression of shareholders' preferential subscription rights related to the abovementioned issue(s) in favor of the holding YA Global Master SPV, managed by the investment company Yorkville Advisors LLC. This resolution was approved by 90.43% of the cast votes;
- A delegation of authority to enable one or more reserved capital increases, for a maximum nominal sum of four hundred thousand Euros (€400,000), by offsetting liquid payable receivables on the Company, through the issue of new ordinary shares of the Company or notes giving the right to subscribe to such shares; the authorization of the corresponding capital increase(s); the suppression of shareholders' preferential subscription rights related to the abovementioned issue(s) in favor of the holding YA Global Master SPV, managed by the investment company Yorkville Advisors LLC. This resolution was approved by 92.34% of the cast votes.

**About GENFIT:**

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). [www.genfit.com](http://www.genfit.com)

**Contacts:**

**GENFIT**

Jean-François Mouney – CEO & Chairman of the Management Board

Ph. +333 2016 4000

**MILESTONES – Press Relations**

Bruno Arabian

Ph. +33 1 7544 8740 / +336 8788 4726 – [barabian@milestones.fr](mailto:barabian@milestones.fr)